Why the right patient profile matters with Arthrosamid

Not every patient with knee osteoarthritis will benefit from Arthrosamid — and that distinction matters more here than with many other injectable options.

Arthrosamid is a 2.5% polyacrylamide hydrogel (PAAG) delivered as a single, ultrasound-guided outpatient injection. Once inside the joint, it integrates permanently with the synovial membrane — the tissue lining the knee — forming a cushioning layer that modifies the joint environment and may reduce pain signals associated with synovial inflammation. Crucially, it does not regrow cartilage; it is a symptom-modifying treatment, not a regenerative one.

Because the hydrogel works through the synovium and relies on sufficient residual joint structure, the stage of osteoarthritis and the overall condition of the knee are genuinely relevant clinical considerations — not administrative formalities. Patients at either extreme of the disease spectrum may find the treatment less suitable.

The sections below lay out what published clinical guidance and specialist practice suggest about who falls within that window, and who does not — as a starting point before any formal assessment.

The typical patient who responds well

Most people who respond well to Arthrosamid share a recognisable picture: persistent knee pain that has not lifted despite doing the right things first.

In practice, that tends to mean someone in their forties, fifties, or sixties — though age is not a hard criterion; disease stage and overall joint condition matter more. The pain is significant enough to affect day-to-day life: interrupted sleep, difficulty walking any useful distance, reduced capacity at work or during leisure. Crucially, it has not responded adequately to conservative care — a course of physiotherapy, weight management where relevant, anti-inflammatory medication, and typically at least one prior injection such as a corticosteroid or hyaluronic acid.

For many patients in this position, the next step on a conventional pathway would be joint replacement — and that is not yet a step they are ready to take. Some are considered too young for a primary replacement; others cannot manage a prolonged surgical recovery; others simply want to extend the window before that decision becomes necessary. Arthrosamid appeals in this context partly because it is a single injection with a potentially durable effect, rather than a treatment requiring regular repeat appointments.

One point worth establishing before the more detailed sections below: Arthrosamid is indicated for osteoarthritis. Patients whose knee pain originates from an inflammatory condition such as rheumatoid arthritis are not suitable candidates — the underlying disease process is different, and the contraindications section covers this in full.

OA severity and the Kellgren-Lawrence grading window

Severity staging sits at the centre of any Arthrosamid candidacy assessment, and the most widely used framework is the Kellgren-Lawrence (KL) scale — a four-point system applied to plain X-ray images that describes how far the joint has deteriorated. In plain terms, the score reflects how much space remains between the bones (where cartilage once sat) and whether osteophytes — bony spurs that form as the joint reacts to wear — are present and how prominent they are.

The scale runs from grade 0 (no changes visible) through grade 1 (possible osteophytes, space preserved) to grade 4, where joint space has been almost entirely lost and the bones are in near-direct contact — what is often described clinically as bone-on-bone.

Why grades 2 and 3 represent the clinical sweet spot

Published evidence and specialist practice consistently identify KL grades 2 and 3 (mild-to-moderate OA) as the range where Arthrosamid is most likely to produce reliable results. At these stages, residual cartilage remains and the synovial tissue is still present in sufficient quantity for the hydrogel to integrate effectively. The inflammatory signalling that drives much of the pain in OA — and which the PAAG mechanism targets — is active and accessible.

Grade 1, by contrast, is typically managed conservatively first. When structural change is minimal, physiotherapy, weight optimisation, and anti-inflammatory medication remain the appropriate starting point.

At grade 4, the clinical picture shifts. With cartilage largely exhausted, the conditions needed for the hydrogel to fulfil its role are compromised, and published guidance generally redirects these patients toward joint replacement as the more predictable pathway. This is not a failure of the treatment — it reflects a different clinical situation that calls for a different solution.

The borderline case

The transition between grade 3 and grade 4 is a genuine grey zone. X-ray alone does not always capture the full picture; MRI can add useful detail on cartilage mapping and the presence of bone marrow lesions, helping to clarify whether a borderline case falls within the viable window. Specialist imaging review at this stage matters more than the KL number alone.

Conditions and circumstances that rule Arthrosamid out

Several factors can rule Arthrosamid out before imaging is even reviewed — and knowing them in advance makes a specialist appointment more productive.

Absolute contraindications

The following circumstances mean Arthrosamid is not suitable:

• Active infection or skin disease at or near the injection site
• Inflammatory or autoimmune arthritis — including rheumatoid arthritis, psoriatic arthritis, and reactive arthritis
• Known allergy to polyacrylamide
• Bleeding disorders (such as haemophilia) or heavy anticoagulant therapy
• Pregnancy or breastfeeding
• Age under 18

BMI threshold

A BMI of 35 kg/m² or above is a formal exclusion criterion; safety and effectiveness have not been established at this level. Manufacturer-derived guidance also notes that outcome predictability begins to reduce above BMI 30, which is factored into clinical assessment even when the hard threshold is not met.

Immune and medical conditions

Immunosuppressive therapy and conditions that significantly affect immune regulation — including Multiple Sclerosis, Addison's disease, and Coeliac disease — are also exclusions. Active cancer treatment falls into the same category.

Timing rules

Two timing criteria catch patients by surprise. Arthroscopy in the same knee within the preceding six months is a contraindication, because the tissue environment needs time to stabilise before a hydrogel can integrate safely. A corticosteroid or hyaluronic acid injection in the same knee within the preceding three months applies for the same reason — both alter the joint environment in ways that can affect how the hydrogel incorporates.

Additional cautions

Poorly controlled diabetes and major dental work planned around the time of the injection are not absolute contraindications but are raised as clinical cautions that warrant discussion during assessment.

A formal consultation — with imaging review — is the appropriate route to establish whether any of these factors applies in an individual case.

What the clinical evidence says about patient outcomes

The published evidence comes primarily from a research programme led by Bliddal and colleagues spanning several years of follow-up. A 6-month prospective study published in 2021 established an early efficacy and safety signal in adults with knee osteoarthritis, reporting meaningful reductions in pain and improvement in function over that period. A 12-month open-label follow-up published in 2024 extended those findings, showing that pain relief and functional gains were sustained rather than diminishing — an important distinction for a single-injection treatment.

The longest available data comes from a 2025 publication reporting five-year outcomes after a single injection. This is genuinely notable for an intra-articular therapy, and published series indicate durability well beyond what is typically seen with repeat-cycle injectable options. That said, the 5-year data is recent and will require further independent scrutiny before it can be treated as a settled reference point.

The honest limitation across this evidence base is that no large placebo-controlled randomised trial has been published to date — the cornerstone studies are prospective and open-label in design. That matters for interpreting the strength of the effect, even if the direction and consistency of the findings are encouraging.

A 2022 case series by Maulana and colleagues added a structural observation: patients with patellofemoral bone marrow lesions showed measurable reductions following a single PAAG injection. This is relevant to the candidacy picture because bone marrow lesions are more common in moderate OA — precisely the stage where clinical outcomes appear most consistent. Taken together, the evidence base clusters around patients with mild-to-moderate disease who have not responded to prior treatments — matching the profile the preceding sections outline.

How eligibility is formally assessed

Establishing whether Arthrosamid is appropriate requires more than matching symptoms to a checklist — it calls for a structured clinical assessment combining imaging review with a detailed account of treatment history and overall health.

The starting point is a weight-bearing X-ray, which allows a specialist to assign a Kellgren-Lawrence grade to each compartment of the knee. Where the plain-film picture leaves questions — particularly around soft-tissue or bone marrow changes — an MRI may be requested before a decision is reached. Alongside the imaging, the consultation maps the patient's BMI, current medications, medical background, and the specific anatomy of the joint against the candidacy criteria outlined in earlier sections.

Once eligibility is confirmed, the injection is carried out as a single ultrasound-guided outpatient appointment. No general anaesthetic, theatre admission, or surgical preparation is required; patients can typically leave the same day.

Arthrosamid is not currently available on the NHS. Patients access it through specialist private outpatient pathways, and the associated costs are a practical consideration worth raising at the initial consultation.

For those at the stage of asking whether this treatment might suit them, an online suitability assessment is available at amsk.co.uk. It does not replace a specialist clinical review, but can help clarify whether pursuing one is a reasonable next step given the candidacy profile this article describes.